What changed from existing technology?
This study introduces a new technique called hex-MASP that allows scientists to map proteins in tissues with high precision and efficiency, making it easier to study how proteins are distributed in the brain and other organs.
The hex-MASP technique introduces a new hexagonal-micro-well design using advanced 3D printing, improving spatial resolution and practicality for whole-tissue proteome mapping.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 3
(MASP) concept for whole-tissue mapping. However, this prototype required substantial development in spatial resolution, practicality, and throughput for pract
Abstract ↗ights into region-specific biological regulations but remains challenging. Previously, we introduced the Micro-scaffold Assisted Spatial Proteomics (MASP
Abstract ↗OpenAlex author affiliations: Jacobs (United States)
Abstract ↗- 제조·규모 확장 근거 미확인
- 장기·실사용 검증 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Validation stage
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
hex-MASP could be used for detailed spatial mapping of proteins in tissues, improving understanding of regional biological processes and antibody distribution in the brain.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.
Evidence and sources
View paper and author affiliations
Open original researchHex -MASP for mapping the whole-tissue spatial proteome and the intrabrain distribution of monoclonal antibodiesProceedings of the National Academy of Sciences · Published 2026-09-03 ↗Author institutions and listed legal entities are separated; only verified exchange and ticker data is linked.